Who is sponsoring NCT00006495?

NCT00006495 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What condition does NCT00006495 study?

NCT00006495 studies HIV Infections.

What drugs are being tested in NCT00006495?

Interventions: ALVAC(2)120(B,MN)GNP (vCP1452), HIV-1 Immunogen.

What is the status of NCT00006495?

NCT00006495 is currently COMPLETED.

Last reviewed 2021-10-28 · How we verify

Augmentation of HIV-Specific Helper and CTL Responses Through Therapeutic Vaccination in Individuals Receiving Potent Suppressive Antiretroviral Therapies

NCT00006495 Phase 1 COMPLETED

The purpose of this study is to see how the vaccines Remune (HIV-1 immunogen) and vCP1452 affect immune responses in patients who also are taking anti-HIV medications. This study also will see if these vaccines are safe to use either alone or in combination. Treatment with anti-HIV drugs does not always keep HIV viral load low and under control. This study will look at the effect of the HIV vaccine, vCP1452, on the immune response and how it works in combination with Remune. Information about immune responses and the safety of these vaccines in HIV-positive patients will be gathered.

Details

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 1
Status	COMPLETED
Enrolment	80
Completion	2004-09

Conditions

HIV Infections

Interventions

ALVAC(2)120(B,MN)GNP (vCP1452)
HIV-1 Immunogen

Countries

United States